ARYA Sciences Acquisition Corp IV

ARYA Sciences Acquisition Corp IV, listed on Nasdaq under the ticker ARYD, is a blank-check company sponsored by an affiliate of Perceptive Advisors, the New York-based healthcare investment manager responsible for the broader series of ARYA Sciences acquisition vehicles. The company completed its initial public offering in 2021 with a focus on identifying targets in the life sciences and biopharmaceutical sectors, continuing Perceptive's established pattern of deploying SPAC capital toward innovative drug development and medical technology businesses. In February 2024, ARYD filed an 8-K with the SEC disclosing a material update in the company's corporate lifecycle. For complete filing history, deal terms, and comparable SPAC analytics on ARYD, sign up for full data access at SpacDesk.